Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress

Core Insights - Celcuity Inc. announced that clinical data from the Phase 3 VIKTORIA-1 trial will be presented at the ESMO Congress, highlighting the efficacy and safety of gedatolisib in treating advanced breast cancer [1][2] Company Overview - Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for various solid tumors, with its lead candidate being gedatolisib, a pan-PI3K and mTORC1/2 inhibitor [3] - The VIKTORIA-1 trial evaluates gedatolisib in combination with fulvestrant, with or without palbociclib, specifically for patients with HR+/HER2- advanced breast cancer [3] - The company is also conducting other clinical trials, including VIKTORIA-2 and CELC-G-201, targeting different cancer indications [3]